24,419 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by Headlands Technologies LLC

Headlands Technologies LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 24,419 shares of the medical equipment provider's stock, valued at approximately $1,760,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of Hologic by 0.8% during the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock worth $847,944,000 after acquiring an additional 81,057 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Hologic by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock valued at $412,159,000 after acquiring an additional 144,838 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock valued at $354,506,000 after buying an additional 24,358 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Hologic by 3.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after acquiring an additional 129,035 shares during the period. Finally, Boston Partners increased its holdings in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock valued at $257,959,000 after purchasing an additional 1,602,463 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a report on Monday, February 3rd. Wolfe Research assumed coverage on shares of Hologic in a research report on Friday, December 13th. They issued a "peer perform" rating on the stock. Argus cut Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, William Blair reaffirmed an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $84.62.

Hologic Stock Down 1.3 %

Shares of NASDAQ:HOLX traded down $0.83 during midday trading on Friday, reaching $60.86. The company had a trading volume of 6,509,048 shares, compared to its average volume of 1,842,488. Hologic, Inc. has a one year low of $59.06 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market capitalization of $13.66 billion, a P/E ratio of 19.20, a PEG ratio of 2.14 and a beta of 0.97. The stock's fifty day moving average price is $64.30 and its 200-day moving average price is $72.59.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.